AUG 18, NEEQ (National Equities Exchange and Quotations) notice shows that Fapon Biotech Inc. was approved to list on the new OTC market and public transfer.

The note shows, the revenues for Fapon in 2014 and 2015 are ￥84.55 million and ￥114 million, the net profit are 33.51 million and 56.71million.

Fapon Biotech Inc. founded in August 2001, is specializing in developing, producing and marketing high quality antigens & antibodies, as well as providing OEM and raw material application technical services. Our main products are genetic engineering recombinant antigens and antibodies, which can be widely used in diagnostic fields, such as infectious diseases, Cardiovascular, Tumor marker and food safety testing.